US Stock MarketDetailed Quotes

JSPR Jasper Therapeutics

Watchlist
  • 5.930
  • +0.260+4.59%
Close Feb 28 16:00 ET
  • 6.000
  • +0.070+1.18%
Post 20:01 ET
88.96MMarket Cap-1.21P/E (TTM)

Jasper Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
10.71%76.24M
42.65%25.29M
2.72%19.89M
-10.29%15.99M
8.07%15.07M
34.50%68.86M
28.94%17.73M
52.36%19.36M
49.02%17.83M
9.15%13.95M
Selling and administrative expenses
19.57%20.42M
41.72%5.51M
20.38%5.43M
3.69%4.7M
15.26%4.77M
3.06%17.08M
-12.88%3.89M
22.46%4.51M
18.34%4.53M
-9.76%4.14M
-General and administrative expense
19.57%20.42M
41.72%5.51M
20.38%5.43M
3.69%4.7M
15.26%4.77M
3.06%17.08M
-12.88%3.89M
22.46%4.51M
18.34%4.53M
-9.76%4.14M
Research and development costs
7.79%55.82M
42.91%19.77M
-2.65%14.46M
-15.05%11.3M
5.03%10.3M
49.55%51.79M
49.05%13.84M
64.58%14.85M
63.45%13.3M
19.75%9.81M
Operating profit
-10.71%-76.24M
-42.65%-25.29M
-2.72%-19.89M
10.29%-15.99M
-8.07%-15.07M
-34.50%-68.86M
-28.94%-17.73M
-52.36%-19.36M
-49.02%-17.83M
-9.15%-13.95M
Net non-operating interest income expense
-2.71%5.06M
-23.99%938K
-10.40%1.28M
0.97%1.45M
26.46%1.39M
641.65%5.2M
254.60%1.23M
453.28%1.43M
1,460.87%1.44M
54,700.00%1.1M
Non-operating interest income
-2.71%5.06M
-23.99%938K
-10.40%1.28M
0.97%1.45M
26.46%1.39M
641.65%5.2M
254.60%1.23M
453.28%1.43M
1,460.87%1.44M
54,700.00%1.1M
Other net income (expense)
89.04%-88K
128.89%26K
-108.31%-32K
-112.86%-40K
97.02%-42K
-106.27%-803K
-147.87%-90K
-34.30%385K
-78.80%311K
-113.33%-1.41M
Gain on sale of security
----
----
----
----
----
-107.99%-575K
--0
----
----
-109.50%-575K
Special income (charges)
--0
--0
-94.01%20K
--0
97.38%-20K
-99.69%18K
-67.06%28K
-20.85%334K
-32.80%420K
-116.63%-764K
-Less：Restructuring and merger&acquisition
--0
--0
94.01%-20K
--0
-97.38%20K
99.69%-18K
67.06%-28K
20.85%-334K
32.80%-420K
116.63%764K
Other non- operating income (expenses)
64.23%-88K
122.03%26K
-201.96%-52K
63.30%-40K
68.57%-22K
-113.91%-246K
-151.06%-118K
466.67%51K
-3,533.33%-109K
5.41%-70K
Income before tax
-10.55%-71.27M
-46.68%-24.32M
-6.23%-18.64M
9.31%-14.58M
3.73%-13.73M
-71.06%-64.47M
-25.51%-16.58M
-47.89%-17.54M
-54.56%-16.08M
-546.13%-14.26M
Income tax
Net income
-10.55%-71.27M
-46.68%-24.32M
-6.23%-18.64M
9.31%-14.58M
3.73%-13.73M
-71.06%-64.47M
-25.51%-16.58M
-47.89%-17.54M
-54.56%-16.08M
-546.13%-14.26M
Net income continuous Operations
-10.55%-71.27M
-46.68%-24.32M
-6.23%-18.64M
9.31%-14.58M
3.73%-13.73M
-71.06%-64.47M
-25.51%-16.58M
-47.89%-17.54M
-54.56%-16.08M
-546.13%-14.26M
Minority interest income
Net income attributable to the parent company
-10.55%-71.27M
-46.68%-24.32M
-6.23%-18.64M
9.31%-14.58M
3.73%-13.73M
-71.06%-64.47M
-25.51%-16.58M
-47.89%-17.54M
-54.56%-16.08M
-546.13%-14.26M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-10.55%-71.27M
-46.68%-24.32M
-6.23%-18.64M
9.31%-14.58M
3.73%-13.73M
-71.06%-64.47M
-25.51%-16.58M
-47.89%-17.54M
-54.56%-16.08M
-546.13%-14.26M
Basic earnings per share
20.87%-4.89
-8.00%-1.62
22.50%-1.24
34.01%-0.97
36.42%-1.03
40.17%-6.18
58.33%-1.5
50.00%-1.6
49.31%-1.47
-170.00%-1.62
Diluted earnings per share
20.87%-4.89
-8.00%-1.62
22.50%-1.24
34.01%-0.97
36.42%-1.03
40.17%-6.18
58.33%-1.5
50.00%-1.6
49.31%-1.47
-170.00%-1.62
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 10.71%76.24M42.65%25.29M2.72%19.89M-10.29%15.99M8.07%15.07M34.50%68.86M28.94%17.73M52.36%19.36M49.02%17.83M9.15%13.95M
Selling and administrative expenses 19.57%20.42M41.72%5.51M20.38%5.43M3.69%4.7M15.26%4.77M3.06%17.08M-12.88%3.89M22.46%4.51M18.34%4.53M-9.76%4.14M
-General and administrative expense 19.57%20.42M41.72%5.51M20.38%5.43M3.69%4.7M15.26%4.77M3.06%17.08M-12.88%3.89M22.46%4.51M18.34%4.53M-9.76%4.14M
Research and development costs 7.79%55.82M42.91%19.77M-2.65%14.46M-15.05%11.3M5.03%10.3M49.55%51.79M49.05%13.84M64.58%14.85M63.45%13.3M19.75%9.81M
Operating profit -10.71%-76.24M-42.65%-25.29M-2.72%-19.89M10.29%-15.99M-8.07%-15.07M-34.50%-68.86M-28.94%-17.73M-52.36%-19.36M-49.02%-17.83M-9.15%-13.95M
Net non-operating interest income expense -2.71%5.06M-23.99%938K-10.40%1.28M0.97%1.45M26.46%1.39M641.65%5.2M254.60%1.23M453.28%1.43M1,460.87%1.44M54,700.00%1.1M
Non-operating interest income -2.71%5.06M-23.99%938K-10.40%1.28M0.97%1.45M26.46%1.39M641.65%5.2M254.60%1.23M453.28%1.43M1,460.87%1.44M54,700.00%1.1M
Other net income (expense) 89.04%-88K128.89%26K-108.31%-32K-112.86%-40K97.02%-42K-106.27%-803K-147.87%-90K-34.30%385K-78.80%311K-113.33%-1.41M
Gain on sale of security ---------------------107.99%-575K--0---------109.50%-575K
Special income (charges) --0--0-94.01%20K--097.38%-20K-99.69%18K-67.06%28K-20.85%334K-32.80%420K-116.63%-764K
-Less：Restructuring and merger&acquisition --0--094.01%-20K--0-97.38%20K99.69%-18K67.06%-28K20.85%-334K32.80%-420K116.63%764K
Other non- operating income (expenses) 64.23%-88K122.03%26K-201.96%-52K63.30%-40K68.57%-22K-113.91%-246K-151.06%-118K466.67%51K-3,533.33%-109K5.41%-70K
Income before tax -10.55%-71.27M-46.68%-24.32M-6.23%-18.64M9.31%-14.58M3.73%-13.73M-71.06%-64.47M-25.51%-16.58M-47.89%-17.54M-54.56%-16.08M-546.13%-14.26M
Income tax
Net income -10.55%-71.27M-46.68%-24.32M-6.23%-18.64M9.31%-14.58M3.73%-13.73M-71.06%-64.47M-25.51%-16.58M-47.89%-17.54M-54.56%-16.08M-546.13%-14.26M
Net income continuous Operations -10.55%-71.27M-46.68%-24.32M-6.23%-18.64M9.31%-14.58M3.73%-13.73M-71.06%-64.47M-25.51%-16.58M-47.89%-17.54M-54.56%-16.08M-546.13%-14.26M
Minority interest income
Net income attributable to the parent company -10.55%-71.27M-46.68%-24.32M-6.23%-18.64M9.31%-14.58M3.73%-13.73M-71.06%-64.47M-25.51%-16.58M-47.89%-17.54M-54.56%-16.08M-546.13%-14.26M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -10.55%-71.27M-46.68%-24.32M-6.23%-18.64M9.31%-14.58M3.73%-13.73M-71.06%-64.47M-25.51%-16.58M-47.89%-17.54M-54.56%-16.08M-546.13%-14.26M
Basic earnings per share 20.87%-4.89-8.00%-1.6222.50%-1.2434.01%-0.9736.42%-1.0340.17%-6.1858.33%-1.550.00%-1.649.31%-1.47-170.00%-1.62
Diluted earnings per share 20.87%-4.89-8.00%-1.6222.50%-1.2434.01%-0.9736.42%-1.0340.17%-6.1858.33%-1.550.00%-1.649.31%-1.47-170.00%-1.62
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----------Unqualified Opinion--------

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
LINTEX
920106
+30.00%
LINGOOD
833284
+29.98%
NTGEC
870436
+29.98%
4
CG MED EQUIP.
838810
+29.97%
5
Jiayu Holding
300117
+20.48%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Widespread uptick! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. Chinese stocks l Show More
Chinese Stocks' Wild Rally Hits Pause? Wall Street Still Bets Big on Favorites